Dynamics of Drug Overdose Deaths in the United States During COVID-19

Importance

Drug overdose (OD) deaths in the United States have risen exponentially for four decades and surged further during the COVID 19 pandemic; the drivers of this surge remain unclear.

Objective

To quantify excess OD mortality during COVID 19, separate its temporal components, and identify social, economic, and drug supply factors—especially Economic Impact Payments (EIPs)—linked to those components.

Design, Setting, and Participants

Temporal and spatial analysis of all 50 U.S. states using OD deaths (1979–2023) merged with state level data on COVID-19, unemployment, income, mobility, fentanyl seizures, opioid treatment supply, and EIP timing/amounts.

Methods

A log linear model projected the 40-year exponential trend and seasonality to establish a no-COVID baseline. Pandemic era deviations were modeled with Poisson state fixed effects regressions. Five week moving window t-tests flagged synchronous mortality spikes across states, and a two-way fixed effects event study estimated the elasticity of OD deaths to EIP related income shocks. JP Morgan Chase checking balance data validated the income–mortality link.

Results

From MarchL2020 to May □ 2023, OD deaths exceeded baseline by 67 □ 571 (24.4%). Sustained elevation was positively associated with income (β □ ≈ □ 0.96), fentanyl seizures, unemployment, and COVID-19 case rates, and inversely with methadone distribution. Three short lived spikes aligned with EIP disbursements, raising daily deaths by up to 85 above trend. A 10% rise in relative income increased OD mortality 11%; national checking balance surges and OD deaths were tightly correlated (r □ ≈ □ 0.90).

Conclusions and Relevance

Pandemic era overdose deaths comprise continuing exponential growth, a COVID-19 related sustained rise tied to social disruption, and EIP linked spikes.

Future relief payments should consider staggered disbursement and concurrent harm reduction measures to mitigate overdose risk.